

Revised Draft Agenda
Biocides Working Group Meeting II-2017

7 – 15 March 2017

ECHA Conference Centre (Annankatu 18, Helsinki)
 Meeting room Margot Wallstrom (MW)
 Meeting room K325
 Meeting room Marie Curie (MC)

Coffee break 11:00-11:30

Lunch break 13:00-14:00

Coffee break 15:30-16:00

Tuesday 7 March	09:00-13:00	APCP WG (K325)
	14:00-17:00	
Tuesday 7 March	09:30-13:00	TOX WG (MW)
	14:00-18:00	
Wednesday 8 March	09:00-13:00	TOX WG (MW)
	14:00-18:00	
Wednesday 8 March	09:30-13:00	EFF WG (K325)
	14:00-17:00	
Thursday 9 March	09:00-13:00	EFF WG (K325)
	14:00-16:30	
Tuesday 14 March	09:30-13:00	ENV WG (MC)
	14:00-18:00	
Wednesday 15 March	09:00-13:00	ENV WG (MC)
	14:00-16:00	

Analytical methods and physico-chemical properties Working Group

Chair: Bernhard Krebs

Item 1 – Welcome and apologies

Item 2 – Administrative issues

Item 3 – Agreement of the agenda

For agreement

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

Item 5 – Agreement of the draft minutes from WG-I-2017

Meeting documents:

- *WG I 2017_APCP_7-1_draft minutes*
- *WG I 2017_APCP_7-2_draft minutes*
- *WG I 2017_APCP_7-3_draft minutes*
- *WG I 2017_APCP_7-4_draft minutes*
- *WG I 2017_APCP_gen agenda items_draft minutes*

For agreement

Item 6 – Follow-up of previous working group meetings

6.1 Follow-up of previous working group meetings

Item 7 – Discussion of active substances

7.1 MBO (eCA AT)

PT 02, 06, 11, 12 and 13

Meeting document: *WG II 2017_APCP_7-1*

For discussion/agreement

7.2 HPT (eCA AT)

PT 02, 06, 11 and 13

Meeting document: *WG II 2017_APCP_7-2*

For discussion/agreement

7.3 Cyphenothrin (eCA EL)

PT 18

Meeting document: *WG II 2017_APCP_7-3*

For discussion/agreement

Item 8 – Technical and scientific issues

8.1 Accelerate storage stability

Meeting document: *WG II 2017_APCP_8-1*

For discussion/agreement

8.2 Redefinition of Glucoprotamin

Meeting document: *WG II 2017_APCP_8-2*

For discussion/agreement

8.3 Commodity chemicals – information requirements on identity and analytical methods

Meeting document: *WG II 2017_APCP_8-3*

For discussion/agreement

Item 9 – AOB

9.1 Update on Union Authorisation

SECR to inform

For information

Human Health Working Group

Chair: Antero Airaksinen

Item 1 – Welcome and apologies

Item 2 – Administrative issues

Item 3 – Agreement of the agenda

For agreement

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

Item 5 – Agreement of the draft minutes from WG-I-2017

Meeting documents:

- *WGI2017_TOX_6-1_Draft minutes*
- *WGI2017_TOX_6-2_Draft minutes*
- *WGI2017_TOX_6-3_Draft minutes*
- *WGI2017_TOX_6-4_Draft minutes*
- *WGI2017_TOX_minutes_draft.docx*

For agreement

Item 6 – Discussion of active substances

6.1 MBO (eCA AT)

PT 2, 6, 11, 12 and 13

Meeting document: *WGII2017_TOX_6-1*

For discussion/agreement

6.2 HPT (eCA AT)

PT 2, 6, 11 and 13

Meeting document: *WGII2017_TOX_6-2*

For discussion/agreement

6.3 Cyphenothrin (eCA EL)

PT 18

Meeting document: *WGII2017_TOX_6-3*

For discussion/agreement

Item 7 – Technical and guidance related issues

7.1 Update on guidance development

SECR to inform

For information

- 7.2 Update on Ad hoc Working Group - Human Exposure**
SECR to inform
For information
- 7.3 Update on Ad hoc Working Group – Assessment of residue transfer to food (ARTFood)**
SECR to inform
For information
- 7.4 WG discussions on issues related to classification and labelling**
Meeting document: *WGII2017_TOX_7-4*
For discussion/agreement
- 7.5 Data requirements for precursors of *in situ* generated active substances**
Meeting document: *WGII2017_TOX_7-5*
For discussion/agreement
- 7.6 Consumer exposure to iodine residues in milk due to teat disinfection**
Meeting document: *WGII2017_TOX_7-6*
For discussion/agreement
- 7.7 Product residues from paper used for food/feed packaging (PT 12)**
Meeting document: *WGII2017_TOX_7-7*
For discussion/agreement
- 7.8 Information on batches used in toxicity testing**
Meeting document: *WGII2017_TOX_7-8*
For discussion/agreement

Item 8 – AOB

- 8.1 Update on Union Authorisation**
SECR to inform
For information
- 8.2 Other information & lessons learned**
SECR/WG members to inform and to reflect on the experience gained
For information

Efficacy Working Group
Chair: Katarzyna Szymankiewicz

Item 1 – Welcome and apologies

Item 2 – Administrative issues

Item 3 – Agreement of the agenda

For agreement

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

Item 5 – Agreement of the draft minutes from WG-I-2017

Meeting documents:

- WGI2017_EFF_6-1_draft_minutes.docx
- WGI2017_EFF_6-2_draft_minutes.docx
- WGI2017_EFF_6-3_draft_minutes.docx
- WGI2017_EFF_6-4_draft_minutes.docx
- WGI2017_EFF_6-5_draft_minutes.docx
- WGI2017_EFF_draft_minutes.docx

For agreement

Item 6 – Discussion of active substances

6.1 MBO (eCA AT)

PT 2, 6, 11, 12 and 13

Meeting document: WGII2017_EFF_6-1

For discussion/agreement

6.2 HPT (eCA AT)

PT 2, 6, 11 and 13

Meeting document: WGII2017_EFF_6-2

For discussion/agreement

Item 7 – Technical and guidance related issues

7.1 Update on guidance development (ECHA)

For information

7.2 Appendix 4 of the PT8 efficacy guidance related to Annex A of EN 599-1 (FR)

Meeting document: WGII2017_EFF_7-2

For discussion

7.3 PT11&12 matrix claim (FR)

Meeting document: WGII2017_EFF_7-3

For discussion

7.4 Interpretation of PT8 efficacy guidance for use class 2 (NL)

Meeting document: WGII2017_EFF_7-4

For discussion

7.5 PT5 efficacy guidance (ECHA)

Meeting document: WGII2017_EFF_7-5

For discussion

Item 8 – AOB

8.1 'Service life' claims made for PT8 products (UK)

Meeting document: WGII2017_EFF_8-1

For discussion

8.2 Testing to prove that co-formulants are not active (NL)

Meeting document: WGII2017_EFF_8-2

For discussion

8.3 Performance for algacidal products with aesthetic claims (DE)

Meeting document: WGII2017_EFF_8-3

For discussion

8.4 Relationship of label and marketing claims (DE)

Meeting document: WGII2017_EFF_8-4

For discussion

8.5 TAB – proposal for inclusion (ECHA)

Meeting document: WGII2017_EFF_8-5

For discussion

8.6 Update on Union Authorisation (ECHA/eCAs)

Meeting document: WGII2017_EFF_8-6

For information

8.7 DE concerns on OECD Guidance Document for Hard Non-Porous Surfaces

For information

8.8 Other information & lessons learned (ECHA)

SECR/WG members to inform and to reflect on the experience gained

For information

Environment Working Group
Chair: Heike Schimmelpfennig

Item 1 – Welcome and apologies

Item 2 – Administrative issues

Item 3 – Agreement of the agenda

For agreement

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

Item 5 – Agreement of the draft minutes from WG-I-2017

Meeting documents:

- *WGI2017_ENV_6-1_Draft minutes*
- *WGI2017_ENV_6-2_Draft minutes*
- *WGI2017_ENV_6-3_Draft minutes*
- *WGI2017_ENV_6-4_Draft minutes*
- *WGI2017_ENV_General_Draft minutes*

For agreement

Item 6 – Discussion of active substances

6.1 Cyphenothrin (eCA EL)

PT 18

Meeting document: *WGII2017_ENV_6-1*

For discussion/agreement

6.2 Agreement on harmonised endpoints for pyrethroid metabolites

imiprothrin (UK), cyphenothrin (EL)

Meeting document: *WGII2017_ENV_6-2*

For discussion/agreement

6.3 MBO (eCA AT)

PT 2, 6, 11, 12 and 13

Meeting document: *WGII2017_ENV_6-3*

For discussion/agreement

6.4 HPT (eCA AT)

PT 2, 6, 11 and 13

Meeting document: *WGII2017_ENV_6-4*

For discussion/agreement

Item 7 – Technical/guidance related issues (including AHEE members)

7.1 Update on guidance development and work of the AHEE (ECHA)

Meeting document: WGII2017_ENV_7-1

For information

7.2 Data requirements for precursors of *in situ* generated active substances (ECHA)

Meeting documents: WGII2017_ENV_7-2

For discussion/agreement

7.3 Outcome of the PT 18 Expert Group meeting (PT 18 - stable and manure applications) (ECHA)

Meeting documents: WGII2017_ENV_7-3

For discussion/agreement

7.4 Information on batches used in ecotoxicity testing (ECHA)

Meeting documents: WGII2017_ENV_7-4

For discussion/agreement

7.5 Harmonisation of PT 21 freshwater scenarios (NL)

Meeting documents: WGII2017_ENV_7-5

For information/discussion

7.6 Outcome of e-consultations initiated in Q4 2016/Q1 2017 (DK, UK, ECHA)

eCAs having initiated e-consultations to report on the outcome

For information

7.7 New developments on mixture toxicity (DE)

Meeting documents: WGII2017_ENV_7-7

For information

Item 8 – AOB

8.1 Update on Union Authorisation

SECR to inform

For information

8.2 Other information & lessons learned

SECR/WG members to reflect on the experience gained

For information